Pfizer's US stocks surged 6% in pre-market trading. Reports indicate that Pfizer is advancing the development of a daily weight-loss drug and will conduct dose optimization studies in the second half of the year.<figure class="image"><img src="https://pub.pbkrs.com/cms/2024/0/hkihC6EtN5qqvTpwmc1pJLrLMXh1iiyu.jpg?x-oss-process=style/lg" original-src="https://pub.pbkrs.com/cms/2024/0/hkihC6EtN5qqvTpwmc1pJLrLMXh1iiyu.jpg"/></figure>The news release on Pfizer's official website is as follows:<figure class="image"><img src="https://pub.pbkrs.com/cms/2024/0/iGEY8AUc2an4bfrdVpTX9v3jJS3Z25td.jpg?x-oss-process=style/lg" original-src="https://pub.pbkrs.com/cms/2024/0/iGEY8AUc2an4bfrdVpTX9v3jJS3Z25td.jpg"/></figure>Pfizer stated that it will conduct research on an improved version of its experimental obesity drug danuglipron in the second half of 2024.Last year, Pfizer announced that due to concerns about liver safety, it abandoned a once-daily pill and shifted its focus to the development of danuglipron. Pfizer is testing a once-daily modified release formulation of danuglipron, as well as a twice-daily formulation.Previously, Novo Nordisk and Eli Lilly, the largest players in the weight-loss drug market, are currently facing supply shortages, and both companies are looking for ways to expand production capacity.As a newcomer disrupting the market, Pfizer is expected to get a piece of the pie. Goldman Sachs previously estimated that the weight-loss drug market will reach $100 billion by 2030.The entire weight-loss concept stock sector has risen by 44.9% year-to-date in 2024.

The weight loss drug market is in short supply, and Pfizer, as a new player, is expected to get a piece of the pie. Goldman Sachs: By 2030, the weight loss drug market is expected to reach $100 billion

- Pfizer's pre-market stock surged by 6% on news of advancing daily weight-loss pill development with dose optimization studies planned for the second half of the year. Pfizer aims to research an improved version of its experimental obesity drug, danuglipron, by late 2024, focusing on liver safety concerns and shifting from a once-daily pill to different formulations. With Pfizer entering the weight-loss market alongside major players like Novo Nordisk and Eli Lilly, the sector has seen a 44.9% increase in 2024, with Goldman Sachs projecting a $1 trillion market size by 2030.

Pfizer's stock price once surged by 6% in a straight line, targeting oral weight-loss miracle drugs